Search…

Lates News

21/06/2025

Norway and Nord released the early results of the clinical trial for the hypoglycemic drug Amycretin. Amycretin showed signs of improving blood sugar levels. In the study, Amycretin demonstrated a weight loss effect of 24.3%.

Latest

3 m ago

Shenzhen Energy and Huawei collaborate on developing a new energy meteorological power forecasting large model.

9 m ago

When asked about the news of the rumored sale of Maserati, a spokesperson for Stellantis said, "Forgive me for being blunt, but Maserati is not for sale."

14 m ago

Micron Technology (MU.US) announces upcoming financial results and receives target price upgrade from Wedbush.

14 m ago

On June 21, according to the Novo Nordisk website, Novo Nordisk announced the results of the Phase 3b STEPUP trial for non-diabetic obese patients at the American Diabetes Association (ADA) scientific meeting in Chicago. The data showed that during the 72-week treatment period, higher doses of Wegovy (semaglutide 7.2mg) led to an average weight loss of 21% in obese patients compared to placebo, with one-third of participants achieving a weight loss of 25% or more. The safety and tolerability of the higher dose of Wegovy (7.2mg) was consistent with the 2.4mg dose.

19 m ago

The new augmented reality program can assist users in independently completing professional tasks.

See all latest

+852 - 60190728

gmteight@futurecultural.com

Customer Support

Commercial Services